Press releases

Oxford BioMedica completes patient recruitment into RetinoStat® Phase I trial

-- Planned 21 patients dosed in “wet" age-related macular degeneration (wet AMD) US Phase I trial


Oxford, UK – 7 April 2014: Oxford BioMedica plc (LSE: OXB), (“the Company”) the leading gene-based biopharmaceutical company, today announces that it has completed the planned recruitment of 21 patients into its Phase I trial of RetinoStat®, a lentiviral vector based treatment for neovascular wet AMD. Each patient has been treated with a single subretinal administration of RetinoStat® which leads to the production of two anti-angiogenic proteins - endostatin and angiostatin.

The industry standard treatments for wet AMD and other related ocular conditions achieved global sales in excess of US$6.0 billion in 20131. On the basis of pre-clinical data, it is anticipated that RetinoStat® may require only a single administration. If confirmed, this would give the product a significant advantage over currently available treatments in the market that require frequent, repeated administration.

The ongoing open-label study is evaluating three dose levels, in four cohorts, to assess safety and aspects of biological activity in the eye. Analysis of patient samples has shown a substantial increase above baseline levels of both endostatin and angiostatin proteins in the eye following a single administration of RetinoStat®; protein expression has been sustained to 12 months (the longest time-point assessed to date in the first three cohorts); and a clear proportional dose response has been seen. All patients are being regularly followed up and indicative results from the study are expected towards the end of 2014. For further information see

RetinoStat® is the remaining development programme under Oxford BioMedica’s 2009 ocular collaboration with Sanofi. Sanofi has an option under the collaboration to enter a development and commercialisation license for RetinoStat®. In February 2014, Oxford BioMedica concluded a licence agreement with Sanofi for the development and commercialisation of StarGen™ and UshStat®, the two other products covered by the collaboration agreement.

Commenting on the news, John Dawson, Chief Executive Officer of Oxford BioMedica, said:

“We are delighted to announce the completion of recruitment into the Phase I RetinoStat®study. This trial was the first to directly administer a lentiviral vector-based treatment in the eye and could pave the way to bringing life-changing eye treatments to patients. We now look forward to the results from the study and reviewing these with our partner Sanofi later this year.” 

source: Novartis/Roche/Regeneron


Notes to editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sarah MacLeod, Head of Communications
Tel: +44 (0)1865 783 000

Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700